Cytovation Strengthens its Board of Directors for Next Phase of Development
/PRNewswire/ -- Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane...
Source: prnewswire.co.uk